Physician profile

Eunhye An

Physician Assistant · Baltimore, MD

NPI 1285144832

$596.03

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$97.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ethicon US, LLC $211.82 2021-2024 Enseal, Ethicon
Abbvie INC. $196.44 2021-2023
Nestle Healthcare Nutrition INC. $54.64 2022
Merck Sharp & Dohme LLC $27.11 2021-2022
Baxter Healthcare $26.70 2022
Janssen Pharmaceuticals, INC $19.58 2021
Regeneron Healthcare Solutions, INC. $17.77 2021
Janssen Biotech, INC. $15.13 2021
Boston Scientific Corporation $14.63 2021
Novartis Pharmaceuticals Corporation $12.21 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eunhye An

$596.03

in general payments reported 2019-2025

Years
2021-2024
Top company
Ethicon US, LLC

https://glasscript.com/doctor/11020949/eunhye-an

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.